For free samples, call 1-866-318-6977

For free samples, call 1-866-318-6977

IMPORTANT CONTACTS
THAT CAN HELP SUPPORT YOU

Support and Service

The following resources may be useful when helping patients start and stay on the subcutaneous (SC) and intravenous (IV) formulations of COSENTYX®.

Name

Phone/Fax

COSENTYX® Connect Support Program

Monday – Friday, excluding holidays, 8:00 AM8:00 PM ET

T:

1-844-COSENTYX (1-844-267-3689)

(1-844-267-3689)

F:

1-844-666-1366 or 1-800-343-9117

or 1-800-343-9117

COSENTYX Co-Pay Program

Monday – Friday, excluding holidays, 8:00 AM8:00 PM ET

T:

1-844-COSENTYX (1-844-267-3689)

(1-844-267-3689)

Covered Until You’re Covered Program

Monday – Friday, 9:00 AM – 6:00 PM ET

T:

1-844-COSENTYX (1-844-267-3689) or
1-919-459-5351

(1-844-267-3689) or

1-919-459-5351

F:

1-800-914-0651

CoverMyMeds®

Monday – Friday, 8:00 AM – 11:00 PM ET

Saturday, 8:00 AM – 6:00 PM ET

T:

1-866-452-5017

Novartis Patient Assistance
Foundation (NPAF)

Monday – Friday, 8:00 AM – 8:00 PM ET

T:

1-800-277-2254

F:

1-855-817-2711

Novartis Customer Service (NowNova)

Monday – Friday, 8:30 AM – 5:00 PM ET

T:

1-888-NOW-NOVA (1-888-669-6682)

(1-888-669-6682)

Find an Infusion Center

The National Infusion Center Association (NICA) tool conveniently locates the infusion centers near you and your patients. Novartis Pharmaceuticals Corporation does not endorse or recommend any specific infusion center.

COSENTYX Returns for the IV formulation

Contact us with questions about returns of COSENTYX. For returns of product damaged in shipment, please contact your distributor.

T:

1-800-526-0175

E:

tradeoperations.phuseh @novartis.com

IV Dosing Calculator for COSENTYX

Information to help you get appropriate patients started on the IV formulation of COSENTYX, including a dosing calculator, administration steps, and an instructional video.

IV Distributors

The IV formulation of COSENTYX is available for buy and bill through the following distributors. Novartis does not recommend the use of any particular distributor.

Name

Phone

T:

1-877-599-7748

F:

1-800-862-6208

T:

1-800-772-4346

F:

1-800-329-9109

T:

1-866-625-2679

T:

1-877-625-2566

F:

1-888-752-7626

T:

1-855-477-9800

F:

1-800-800-5673

T:

1-800-768-2002

F:

1-615-256-4194

IV Group Purchasing Organizations (GPOs)

If you intend to work with a GPO, you can order the IV formulation of COSENTYX through the following companies. Novartis does not recommend the use of any particular GPO.

Name

Phone

Cornerstone Rheumatology GPO

For Cardinal Health SD/Metro Medical customers

T: 1-800-768-2002

MosaicGPO Solutions

For Cardinal Health SD/Metro Medical customers

T: 1-800-768-2002

VitalSource GPO

For Cardinal Health SD/Metro Medical customers

T: 1-877-453-3972

Matrix GPO

For CuraScript customers

T: 1-888-263-9982

Onmark GPO

For McKesson Specialty Care and Plasma and Biologics customers

T: 1-800-482-6700

Unity Oncology

For McKesson Specialty Care and Plasma and Biologics customers

T: 1-800-482-6700

IPN

For ASD Healthcare (Amerisource Bergen/Cencora) and Besse Medical Customers

T: 1-610-727-7000

ION

For ASD Healthcare (Amerisource Bergen/Cencora) and Besse Medical Customers

T: 1-610-727-7000

Vizient

For acute care customers

T: 1-800-842-5146

Cardinal Health

For acute care customers

T: 1-800-926-3161

Our Partners

To best educate and care for our patients, COSENTYX is proud to partner with these outstanding organizations.

Covered Until You're Covered

Biologic Coordinators of Dermatology

https://www.bcofdermatology.com
NORM-2020-logo-CMYK

National Organization of Rheumatology Management

https://normgroup.org
Rheumatology Advanced Practice Providers

Rheumatology Advanced Practice Providers

https://www.rhapp.org
Rheumatology Advanced Practice Providers

Rheumatology Nurses Society

https://rnsnurse.org
UR_Revised_Logo_Blue

United Rheumatology

https://ureqa.org

3/24  304272

Expand ISI

INDICATIONS

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

COSENTYX® (secukinumab) is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy.

WARNINGS AND PRECAUTIONS

Infections

Collapse ISI

INDICATIONS

COSENTYX® (secukinumab) is indicated for the treatment of moderate to severe plaque psoriasis (PsO) in patients 6 years and older who are candidates for systemic therapy or phototherapy.

COSENTYX is indicated for the treatment of active psoriatic arthritis (PsA) in patients 2 years of age and older.

COSENTYX is indicated for the treatment of adult patients with active ankylosing spondylitis (AS).

COSENTYX is indicated for the treatment of adult patients with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation.

COSENTYX is indicated for the treatment of active enthesitis-related arthritis (ERA) in patients 4 years of age and older.

COSENTYX is indicated for the treatment of adult patients with moderate to severe hidradenitis suppurativa (HS).

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

COSENTYX is contraindicated in patients with a previous serious hypersensitivity reaction to secukinumab or to any of the excipients in COSENTYX. Cases of anaphylaxis have been reported during treatment with COSENTYX.

WARNINGS AND PRECAUTIONS

Infections

COSENTYX may increase the risk of infections. In clinical trials, a higher rate of infections was observed in COSENTYX treated subjects compared to placebo-treated subjects. In placebo-controlled clinical trials in subjects with moderate to severe PsO, higher rates of common infections, such as nasopharyngitis (11.4% versus 8.6%), upper respiratory tract infection (2.5% versus 0.7%) and mucocutaneous infections with candida (1.2% versus 0.3%) were observed in subjects treated with COSENTYX compared to placebo-treated subjects. A similar increase in risk of infection in subjects treated with COSENTYX was seen in placebo‑controlled trials in subjects with PsA, AS and nr-axSpA. The incidence of some types of infections, including fungal infections, appeared to be dose‑dependent in clinical trials.

In the postmarketing setting, serious and some fatal infections have been reported in patients treated with COSENTYX.

Exercise caution when considering the use of COSENTYX in patients with a chronic infection or a history of recurrent infection. Instruct patients to seek medical advice if signs or symptoms suggestive of an infection occur. If a patient develops a serious infection, monitor the patient closely and discontinue COSENTYX until the infection resolves.

Pre-treatment Evaluation for Tuberculosis

Evaluate patients for tuberculosis (TB) infection prior to initiating treatment with COSENTYX. Avoid administration of COSENTYX to patients with active TB infection. Initiate treatment of latent TB prior to administering COSENTYX. Consider anti-TB therapy prior to initiation of COSENTYX in patients with a past history of latent or active TB in whom an adequate course of treatment cannot be confirmed. Monitor patients closely for signs and symptoms of active TB during and after treatment.

Inflammatory Bowel Disease

Inflammatory Bowel Disease Inflammatory Bowel Disease (IBD) exacerbations, in some cases serious and/or leading to discontinuation of COSENTYX, occurred in COSENTYX treated subjects during clinical trials in PsO, PsA, AS, nr-axSpA, and HS. In adult subjects with HS, the incidence of IBD was higher in subjects who received COSENTYX 300 mg every 2 weeks (Ulcerative Colitis [UC] 1 case, EAIR 0.2/100 subject-years; Crohn’s Disease [CD] 1 case, EAIR 0.2/100 subject-years) compared to subjects who received COSENTYX 300 mg every 4 weeks (IBD 1 case, EAIR 0.2/100 subject-years). In addition, new onset IBD cases occurred in subjects treated with COSENTYX in clinical trials. In an exploratory trial in 59 subjects with active Crohn’s disease [COSENTYX is not approved for the treatment of Crohn’s disease], there were trends toward greater disease activity and increased adverse reactions in subjects treated with COSENTYX as compared to placebo-treated subjects.

Exercise caution when prescribing COSENTYX to patients with IBD. Patients treated with COSENTYX should be monitored for signs and symptoms of IBD.

Eczematous Eruptions

In postmarketing reports, cases of severe eczematous eruptions, including atopic dermatitis‑like eruptions, dyshidrotic eczema, and erythroderma, were reported in patients receiving COSENTYX; some cases resulted in hospitalization. The onset of eczematous eruptions was variable, ranging from days to months after the first dose of COSENTYX.

Treatment may need to be discontinued to resolve the eczematous eruption. Some patients were successfully treated for eczematous eruptions while continuing COSENTYX.

Hypersensitivity Reactions

Anaphylaxis and cases of urticaria occurred in COSENTYX treated subjects in clinical trials. If an anaphylactic or other serious allergic reaction occurs, administration of COSENTYX should be discontinued immediately and appropriate therapy initiated.

The removable caps of the COSENTYX Sensoready® pen and the COSENTYX 1 mL and 0.5 mL prefilled syringes contain natural rubber latex, which may cause an allergic reaction in latex-sensitive individuals. The safe use of the COSENTYX Sensoready pen or prefilled syringe in latex-sensitive individuals has not been studied.

Immunizations

Prior to initiating therapy with COSENTYX, consider completion of all age-appropriate immunizations according to current immunization guidelines. COSENTYX may alter a patient’s immune response to live vaccines. Avoid use of live vaccines in patients treated with COSENTYX.

MOST COMMON ADVERSE REACTIONS

Most common adverse reactions (>1%) are nasopharyngitis, diarrhea, and upper respiratory tract infection.

Please see full Prescribing Information, including Medication Guide.